Radius Health Partners with Benuvia Manufacturing on Development of Cannabidiol Oral Solution
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) announced on January 6, 2021 a definitive agreement to acquire the global development and commercialization rights to Benuvia Therapeutics Inc.’s (“Benuvia”) synthetic cannabidiol oral solution (“RAD011”). The Company plans to initiate a pivotal Phase 2/3 study for patients with Prader-Willi syndrome (“PWS”) in the second half of … Read more Radius Health Partners with Benuvia Manufacturing on Development of Cannabidiol Oral Solution